Estados Unidos · Plataformas y datos · MarketBeat
Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows

Resumen detallado
Evolus (NASDAQ:EOLS) executives said the company expects its expanding lineup of injectable aesthetics products to support growth as it prepares for the anticipated launch of Evolysse Sculpt in 2027. At a company event, CEO and President David Moatazedi said Evolus has diversified beyond its flagsh
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)




